Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2477752 | 0.84 | CHRNB2 (0.56) | LTA4HCHRNB2CHRNA4MAPT | |
| SCHEMBL3653085 | 0.77 | APP (0.51) | NOS1NOS2 | |
| SCHEMBL11713528 | 0.76 | LTA4H (0.58) | LTA4HCHRNB2CHRNA4KDM4EALDH1A1 | |
| SCHEMBL10261014 | 0.75 | KDM4E (0.82) | LTA4HCHRNB2CHRNA4KDM4EALDH1A1 | |
| SCHEMBL11543800 | 0.75 | CYP1A2 (0.50) | LMNA | |
| SCHEMBL30862627 | 0.73 | CHRNB2 (0.67) | LTA4HCHRNB2CHRNA4KDM4EALDH1A1 | |
| SCHEMBL16858365 | 0.73 | CHRNB2 (0.67) | LTA4HCHRNB2CHRNA4KDM4EALDH1A1 | |
| SCHEMBL5025139 | 0.73 | CHRNB2 (0.67) | LTA4HCHRNB2CHRNA4KDM4EALDH1A1 | |
| SCHEMBL3652838 | 0.73 | ALDH1A1 (0.58) | LTA4HKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3652757 | 0.72 | MAOB (0.55) | LTA4HALDH1A1SMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2205317-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | Senexis Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009044160-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044160-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HCRTR1, HCRTR2, RTN3 | LTA4H 2888/4885CHRNB2 94/4885CHRNA4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.